VITR Vitrolife AB (publ)

11.56USD117.40 SEK · STO-0.25%Mkt Cap: 1.53B USDP/E: —

Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse…

Key Statistics

Company
Market Cap1.53B USD
Enterprise Value1.62B USD
Revenue (TTM)338.60M USD
Gross Profit196.56M USD
Net Income (TTM)-493.33M USD
Revenue/Share2.51 USD
Last Price11.56 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees1.1K
CountrySE
SectorHealthcare
IndustryMedical Devices
ISINSE0011205202
Valuation
P/E (Trailing)—
P/E (Forward)24.41
PEG2.02
EV/EBITDA16.20
EV/Revenue4.78
P/S4.53
P/B1.92
EPS (TTM)-3.60 USD
EPS (Forward)0.47 USD
52W Range
8.26849% of range15.01
52W High15.01 USD
52W Low8.268 USD
Profitability
Gross Margin58.05%
Oper. Margin19.42%
EBITDA Margin29.51%
Profit Margin-145.70%
ROE-63.49%
ROA-45.06%
ROIC6.60%
ROCE5.46%
Growth
Revenue Growth5.90%
Earnings Growth25.30%
Cash Flow & Leverage
Operating CF62.50M USD
CapEx (TTM)24.31M USD
FCF Margin14.69%
FCF Yield3.24%
Net Debt85.14M USD
Net Debt/EBITDA0.85
Net Debt/FCF1.71
Balance Sheet
Debt/Equity0.20
Current Ratio3.68
Quick Ratio2.82
Book Value/Sh6.02 USD
Cash/Share0.64 USD
Dividends
Fwd Div Rate0.11 USD
Trail. Div Rate0.11 USD
Div. Yield0.93%
5Y Avg Yield0.46%
Payout Ratio33.85%
Ex-Div DateMay 6, 2026
Pay Date—
Splits
Last Split5:1
Split DateMay 17, 2018
Analyst Consensus
Rating—
Target (Mean)13.09 USD
Upside (mean)+13.3%
Target Range10.34 USD – 15.26 USD
10.34+13.3% to mean15.26
# Analysts5
Ownership
Shares Out.132.73M
Float71.02M
Insiders29.72%
Institutions58.39%
Technical
SMA 5010.10 (+14.5%)
SMA 2009.530 (+21.3%)
Beta1.66
S&P 52W Chg12.00%
Avg Vol (30d)198.15K
Avg Vol (10d)243.46K
Technical Indicators
RSI (14)67.6
MACD4.4773
MACD Signal5.2225
MACD Hist.-0.7452
BB Upper12.12 USD
BB Middle11.44 USD
BB Lower10.76 USD
BB Width11.89%
ATR (14)0.2977 USD
Vol Ratio (20d)1.19x

About Vitrolife (STO: VITR)

›

Vitrolife (STO: VITR) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 1,088 employees.

The shares were at 117.40 SEK on 19 November 2026, down 18.0% over 52 weeks. Its 52-week range is 84.00 SEK to 152.50 SEK: the price is 23.0% below the high and 39.8% above the low.

Its market capitalisation is 15.58B SEK. It pays a dividend yielding 0.93% (it pays out 34% of its earnings), against a median of 2.36% among the dividend payers in that peer group.

Vitrolife reports return on equity of -63.5%, an operating margin of 19.4% and revenue up 5.9% year over year.

Its debt exceeds its cash by 865.00M SEK, a debt-to-equity ratio of 0.20. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 5 analysts cover the stock; their mean price target of 133.00 SEK is 13.3% above the current price. The next earnings report is expected on 28 January 2027.